Pharmaceutical patent approved for study of medicinal mushroom against triple negative cancer on the Island

The doctors insist that each advance must be patented for the necessary use in patients and their quality of life.

Dr. Michelle Martínez, associate professor in the Department of Biochemistry of the Central University of the Caribbean.

The patent for the discovery of the researcher and associate professor Dr. Michelle Martínez on the use of medicinal mushrooms in the treatment of breast cancer, was patented before the Trust for Science, Technology and Research of Puerto Rico (PRSTRT), on behalf of the Central University of the Caribbean (UCC) and the Canadian company Revive Therapeutics. 

The research was shared with Dr. Fátima Rivas, from St. Jude Children’s Research Hospital; after Dr. Martinez discovered that a compound from the mushroom variety Ganoderma lucidum, which has an anticancer effect. 

“This effect is especially significant against breast cancer and has the potential to treat the most aggressive types of breast cancers, such as triple negative breast cancer and inflammatory breast cancer,” the researchers remarked. 

The elbow abscess was 4 days before the symptoms which lasted 15 days prior to arriving at the ER, it is read or I almost understand that the abscess presented in ER but it was not like that, at home he presented a small abscess that the patient refers opened and healthy at home without going to a doctor for evaluation 

It is read that Patient was discharged very quickly, completed 15 days of IV antibiotics with marked improvement, then coordinated to fulfill the days that would be missing from IV antibiotics treatment to complete a minimum of 8 weeks. 

Dr. Martinez noted that she began conducting research on the fungus Ganoderma lucidum in 2007 and that this represents the goal of every researcher dedicated to science and health. 

Related article: Puerto Rican scientist demonstrates that medicinal mushroom suppresses the migration of triple negative breast cancer cells

“Having succeeded in getting a pharmaceutical company to develop a non-toxic therapeutic alternative for people suffering from this lethal cancer is a great achievement in my scientific career and as a person. This agreement represents the goal of every researcher: to discover new technologies that help the health of human beings. I want to highlight the support I received from the Central University of the Caribbean and the Trust’s Technology Transfer Office to make this agreement possible ”, stated the researcher.

The director of the Trust’s Office of Technology Transfer, Dr. David Gulley, said that this is the first successful license agreement that we have as a result of our collaboration with the UCC. 

“The research team also participated in our 2021 Therapeutic Accelerator Program in cooperation with Columbia University, and received $ 75,000 from the Trust to reduce risk or“ de-risk ”the technology. Successful technology transfer begins with outstanding research, but requires a team and resources to move toward commercialization, ”he said. 

For her part, the president of the UCC, Dr. Waleska Crespo, stated that “this agreement makes history in our institution as it is the first of the patents developed by UCC researchers to reach the commercialization phase. We are very excited about this achievement and we reaffirm our commitment to the development of knowledge through research, which is one of our institutional goals ”.

About the patent 

Revive Therapeutics, Ltd. exclusively licensed the international patent application under the name Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Revive Therapeutics is a life sciences company focused on the research and development of therapies for infectious diseases and rare disorders. 

Dr. Martínez explained that the patent process began in 2019 with the support of the Trust’s Technology Transfer Office (TTO) and that, after filing a provisional patent, an international patent application (PCT) was submitted. To seek to protect the invention internationally, and for it to be published, the license talks began in January of this year. 

On August 9, the exclusive license agreement on the intellectual property of the discovery was signed.


0/Post a Comment/Comments